Anavex Life Sciences Corp (AVXL)

[nidan7500]

3. RESULTS
3.1. Exploratory therapeutic response analysis: Response to blarcamesine (ANAVEX2-73) at week 57
A total of 3,145,630 relations between all available features were explored. Stringent filtering focused on relationships of response at week 57 (end of Part B) reduced the number of associations to only 15 linked to clinical outcomes, as measured by change from baseline (Delta) or rate of decline (Slope) MMSE or ADCS-ADL (Table 2a). Within the 15 relations identified, average blood concentration of blarcamesine (ANAVEX2-73) above 4 ng/mL in Part B increased the probability of improved MMSE outcome 1.88-fold at week 57 (Table 2a). Higher concentrations also increased the probability of improved ADCS-ADL scores (P = .03; Fig. S1c). Lower MMSE baseline scores (<20) increased the relative probability (lift) of worse MMSE outcome by 1.5-fold, while higher MMSE baseline scores (≥20) increased the relative probability of improved MMSE by 1.62-fold, both at week 57.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167374/